UNSPSC 51262606: Imiloxan hydrochloride

This classification denotes an alpha-adrenergic blocking agent C14H16N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X72FO6ZLZY, chemically known as (+/-)-2-(1,4-benzodioxan-2-ylmethyl)-1-ethylimidazole monohydrochloride, but more generally known as imiloxan hydrochloride, which bears US NIH Compound Identifier 172975. Most nations, for tariff and trade purposes, schedule imiloxan hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, IMILOXAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Imiloxan hydrochloride bears US NLM identifiers UMLS ID C2827196 and NCI Concept Code C83793. SMILES: CCN1CCNC1CC2COC3CCCCC3O2.CL.

UNSPSC 51262606 Imiloxan hydrochloride is a Commodity code that covers pharmaceutical products used in emergency response and community health interventions, though recent state and local solicitations under this code reflect broader opioid-response procurement beyond the specific pharmaceutical named in the code's title. State and local governments buying under this code are acquiring naloxone products and complementary drug deactivation systems to support public health initiatives addressing opioid emergencies and substance abuse. Issuing bodies include county health departments and state health and human services agencies; the recent opportunity block shows Seminole County, Florida procuring naloxone and drug deactivation systems for community health delivery, and the Texas Health and Human Services Commission conducting market research on direct-to-manufacturer pharmacy programs that would encompass a wider range of prescription fulfillment.

Activity under the code centers in Florida and Texas based on recent postings. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a July 26, 2023 response deadline; the contract carries a two-year initial term with a one-year renewal option and includes federal compliance requirements tied to potential FEMA funding. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program serving state agencies and self-insured health plans, signaling exploratory procurement activity that may lead to broader formal solicitation. Neither solicitation specifies set-asides for disadvantaged vendors, and both require standard federal compliance including E-Verify and drug-free workplace certification.